Home

Insights

PE

Venus Remedies Ltd P/E Ratio

Venus Remedies Ltd P/E Ratio

download
stocks purchased

₹ 0.5 Cr

Volume transacted

stocks purchased

13.0 K

stocks traded

Last Updated time: 14 Jul 15:30 PM

Image

Venus Remedies Ltd

NSE: VENUSREM

PE

18.3

Last updated : 14 Jul 15:30 PM

Key Highlights

    The P/E Ratio of Venus Remedies Ltd is 18.3 as of 14 Jul 15:30 PM .a1#The P/E Ratio of Venus Remedies Ltd changed from 5.5 on March 2019 to 8.1 on March 2023 . This represents a CAGR of 13.77% over 3 years. a1#The Latest Trading Price of Venus Remedies Ltd is ₹ 390.1 as of 12 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.7. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 35.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Venus Remedies Ltd changed from ₹ 40.91 crore on March 2019 to ₹ 216.48 crore on March 2023 . This represents a CAGR of 39.55% over 5 years. a1#The Revenue of Venus Remedies Ltd changed from ₹ 144.52 crore to ₹ 199.08 crore over 8 quarters. This represents a CAGR of 17.37% a1#The EBITDA of Venus Remedies Ltd changed from ₹ 15.95 crore to ₹ 23.39 crore over 8 quarters. This represents a CAGR of 21.10% a1#The Net Pr of Venus Remedies Ltd changed from ₹ 6.89 crore to ₹ 10.51 crore over 8 quarters. This represents a CAGR of 23.51% a1#The Dividend Payout of Venus Remedies Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Venus Remedies Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Venus Remedies Ltd

Period
Mar '190
Mar '200
Mar '215.5
Mar '228.8
Mar '238.1

Company Fundamentals for Venus Remedies Ltd

Market Cap

521 Cr

EPS

21.3

P/E Ratio (TTM) *

18.3

P/B Ratio (TTM) *

1.1

Day’s High

406.6

Day’s Low

385.75

DTE *

0.1

ROE *

5.8

52 Week High

429.6

52 Week Low

222.0

ROCE *

8.5

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

Image

Venus Remedies Ltd

NSE: VENUSREM

PRICE

390.1

-5.10 (-1.29%)

stock direction

Last updated : 12 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Venus Remedies Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value of Venus Remedies Ltd

Market Value

521

Asset Value

336

0.6 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Venus Remedies Ltd18521
Sun Pharmaceuticals Industries Ltd37378,675
Cipla Ltd28122,093
Divis Laboratories Ltd75120,480
Zydus Lifesciences Ltd30118,217
Dr Reddys Laboratories Ltd20112,137

Key Valuation Metric of Venus Remedies Ltd

Earnings

28 Cr

18.3 X

PE Ratio

Market Cap

₹521.45Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

28 Cr

18.3 X

PE Ratio

Market Cap

₹521.45Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Venus Remedies Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Venus Remedies Ltd

Period
Mar '1941
Mar '2028
Mar '21339
Mar '22359
Mar '23216

* All values are a in crore

×

Historical Revenue of Venus Remedies Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Venus Remedies Ltd

Period
Jun '22145
Sep '22142
Dec '22121
Mar '23159
Jun '2397
Sep '23171
Dec '23146
Mar '24199

* All values are a in crore

×

Historical EBITDA of Venus Remedies Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Venus Remedies Ltd

Period
Jun '2216
Sep '2215
Dec '2212
Mar '2328
Jun '2313
Sep '2321
Dec '2314
Mar '2423

* All values are a in crore

×

Historical Net Profit of Venus Remedies Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Venus Remedies Ltd

Period
Jun '227
Sep '225
Dec '223
Mar '2311
Jun '231
Sep '2310
Dec '237
Mar '2411

* All values are a in crore

×

Historical Dividend Payout of Venus Remedies Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Venus Remedies Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

About Venus Remedies Ltd

About Venus Remedies Ltd

    Incorporated in 1989 Venus Remedies Ltd (formerly known Venus Glucose Pvt Ltd), was converted into Public Limited Company in 1994 and then changed into Venus Remedies Limited. The Company was promoted and managed by Chaudhary & Family. The Company is one of the handful player in pharmaceutical sector to launch injectables globally. It has manufacturing facilities in Panchkula and Baddi , and research and development centre under the name of Venus Medicine Research Centre (in India). In priority, the Company was mainly engaged in I/V Fluids & Injectables, Ceftazidime, Amlodipine, Gliclazide, Lisinopril, etc. The production was started in 1991 with Intravenous/Intramuscular injectible forms at Panchkula district at Haryana. In 1994 it introduced Eye/Ear/Nose drops. The company received the certificate as 'WHO-GMP' as specified by WHO,Geneva. Venus Remedies set up a Cephalosporin project with an Australian collaboration with US-FDA standards at a cost of Rs.4.5 crores. The company is manufacturing injections for the top companies like Panacea Biotech ltd,Morepan Labortories ltd etc. In 2001 with the help of Product Development Committee(PDC) Venus Remedies had introduced 13 new products in the Animal Health Division namely Megox-3000,Paroxin-3000,Pisa-3000,Mical,Ronid,Dexolyte and Detox. The year 2005-06 saw many new milestone achievements by the Company like commercial operation of its most modern and techno-savvy manufacturing unit at Baddi, formation of a WOS in Germany and acquisition of a running, German-GMP certified pharmaceutical unit at Werne, Germany, launch of its second R&D Product after DCGI Approval etc. There was a rigorous activity for development on all fronts and the Company made huge investments in projects at Panchkula, Baddi and now at Werne, Germany for renovations, new Projects and acquisition as well. The Company was the first to launch Injection Meropenem in Paediatric Dosage of 125 mg in its Domestic Marketing during the year 2006-07. It further launched fourth research product, a fixed dose combination of cephalosporin with aminoglycoside under the 'Tobracef' brand in 2008-09. It launched its anti-cancer drug 'Docetaxel' in Europe by end 2011, launched ACHNIL, the once-a-day pain management therapy in India in 2011; launched 'Cytomib', a first-time therapy against blood cancer in 2011; launched 'Taxedol' in three strengths-20 mg, 80 mg and 120 mg in 2012. In 2013, the Company established pre-clinical proof of concept for its Drug -Protein-Polymer- Conjugate (DPPC); introduced Ready-to-Use a Single Vial Taxedol in India; launched 'Trois', a miracle nano-emulsion for arthritic Pain; launched 'Elores' - CSE 1034, a US patent protected product in India, launched its first OTC product 'Ezenus'. In 2014, the Company launched ELORES, an antibiotic to fight superbugs'. In 2021-22, it launched first product in the consumer healthcare space, R3SET - a Pain Management solution. Besides this, Venpocare dealing with Wound Healing was also launched during year 2022. To make internal processes smart and streamlined, many solutions including an automated order processing system, retail billing system, new warehouse (VFC) with barcode automation, etc. were launched. For quicker and more effective decision-making, a BI tool like Tableau was also launched in 2022.

Venus Remedies Ltd News Hub

News

Venus Remedies schedules board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 20 July 202...

Read more

10 Jul 202417:48

News

Venus Remedies edges higher after bagging supply order for oncology drugs from PAHO

Pan American Health Organisation (PAHO) is the world’s oldest international public health ...

Read more

19 Jun 202409:41

News

Venus Remedies soars after bagging Ceftriaxone supply contract from UNICEF

The company had earlier received GMP (Good Manufacturing Practices) approval from UNICEF. ...

Read more

13 Jun 202411:00

News

Venus Remedies schedules board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 30 May 2024...

Read more

21 May 202411:52

News

Venus Remedies secures GMP approval from UNICEF

UNICEF, an esteemed agency of the United Nations, is recognized globally for its efforts i...

Read more

11 Mar 202415:41

News

Venus Remedies schedules board meeting

Venus Remedies will hold a meeting of the Board of Directors of the Company on 14 February...

Read more

03 Feb 202417:07

Product Composition by Percentage (Revenue)

FAQs for PE of Venus Remedies Ltd

What is Venus Remedies Ltd current share price?

The current market price of Venus Remedies Ltd as of July 14, 2024 is ₹390.10.

What is Venus Remedies Ltd's market cap?

Venus Remedies Ltd's market capitalisation stood at ₹521 Cr as of July 14, 2024

What are Venus Remedies Ltd's total net assets?

According to Venus Remedies Ltd's most recent financial filings, the company's net assets total ₹335.6 Cr.

Is Venus Remedies Ltd making a profit or loss?

Venus Remedies Ltd's net Profit as of July 14, 2024 is close to ₹28 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199